Methionine metabolism in an animal model of sepsis.
BACKGROUND
Sepsis is a disease with high incidence and lethality and is accompanied by profound metabolic disturbances. In mammalian methionine metabolism, S-adenosylmethionine (SAM) is produced, which is important in the synthesis of neurotransmitters and glutathione and as an anti-inflammatory agent. The degradation product and antagonist of SAM is S-adenosylhomocysteine (SAH). In this study, we investigated changes in methionine metabolism in a rodent model of sepsis.


METHODS
Sepsis was induced in male Wistar rats (n=21) by intraperitoneal injection of bacterial lipopolysaccharide (10 mg/kg). Controls (n=18) received vehicle only. Blood was collected by cardiac puncture 24 h later. Puncture of the suboccipital fossa was performed to collect cerebrospinal fluid (CSF). Methionine metabolites were measured using stable isotope dilution tandem mass spectrometry. Plasma total homocysteine and cysteine were measured by HPLC using fluorescence detection. Glutathione was assayed using a modified enzymatic microtiter plate assay.


RESULTS
We observed significantly higher plasma levels of SAM (p<0.001) and SAM/SAH ratio (p=0.004) in septic animals. In CSF, there was also a trend for higher levels of SAM in septic animals (p=0.067). Oxidative stress was reflected by an increase in the ratio of oxidized/reduced glutathione in septic animals (p=0.001).


CONCLUSIONS
Sepsis is associated with an increase in SAM/SAH ratio in plasma and CSF in rodents. This indicates an altered methylation potential during sepsis, which may be relevant for sepsis-associated impairment of transmethylation reactions, circulation and defense against oxidative stress. If verified in humans, such findings could lead to novel strategies for supportive treatment of sepsis, as methionine metabolism can easily be manipulated by dietary strategies.
Neurology Department, University Hospital Zurich, Zurich, Switzerland. alexander.semmler@usz.ch
Alexander
A
Semmler
Yvo
Y
Smulders
Eduard
E
Struys
Desiree
D
Smith
Susanna
S
Moskau
Henk
H
Blom
Michael
M
Linnebank
D000818:Animals; D003545:Cysteine / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism; D004195:Disease Models, Animal; D005978:Glutathione / Q000097:blood / Q000378:metabolism; D006710:Homocysteine / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism; D008070:Lipopolysaccharides / Q000633:toxicity; D008297:Male; D008715:Methionine / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism*; D010084:Oxidation-Reduction; D051381:Rats; D012435:S-Adenosylhomocysteine / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism; D012436:S-Adenosylmethionine / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism; D018805:Sepsis / Q000097:blood / Q000134:cerebrospinal fluid / Q000139:chemically induced / Q000378:metabolism*
D008070:Lipopolysaccharides; D006710:Homocysteine; D012436:S-Adenosylmethionine; D012435:S-Adenosylhomocysteine; D008715:Methionine; D005978:Glutathione; D003545:Cysteine